Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
217 Results for "
MCL-1
" in MedChemExpress (MCE) Product Catalog:
Products (217)
217 Results for "MCL-1" in MCE Product Catalog:
Cat. No.: HY-103019BR
CAS No.: 1610408-96-2
Synonyms: (R)-Enitociclib (Standard); (-)-BAY-1251152 (Standard); (-)-VIP152 (Standard)
Research Areas:
(-)-Enitociclib (Standard) is the analytical standard of (-)-Enitociclib (HY-103019B). This product is intended for research and analytical applications. (-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies [1] .
Cat. No.: HY-19482
CAS No.: 630100-90-2
Target:
Research Areas:
E7107 is a pre-mRNA spliceosome inhibitor and apoptosis (Apoptosis) inducer. E7107 binds to spliceosome-associated protein 130, inhibits spliceosome assembly and pre-mRNA splicing, regulates cellular protein expression, induces G1 and G2/M phase cell cycle arrest, triggers DNA damage, alters R-loop levels, reduces CHEK2 expression, impairs transcriptional elongation, and shifts MCL1 splicing toward pro-apoptotic isoforms. E7107 inhibits tumor growth in xenograft models and reduces leukemia burden. E7107 can be used in the research of advanced solid tumors, acute myeloid leukemia, T-cell acute lymphoblastic leukemia, and triple-negative breast cancer [1] .
Synonyms: EU-5346
Target:
Research Areas:
ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction.
Target:
Research Areas:
CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells [1].
Cat. No.: HY-19471
CAS No.: 1010440-84-2
(rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET [1].
Cat. No.: HY-P86907
Synonyms: ARF binding protein 1 antibody; ARF BP1 antibody; ARF-binding protein 1 antibody; ARF-BP1 antibody; ARFBP1 antibody; BJ-HCC-24 tumor antigen antibody; E3 ubiquitin protein ligase HUWE1 antibody; E3 ubiquitin-protein ligase HUWE1 antibody; HECT antibody; HECT domain protein LASU1 antibody; ARF binding protein 1 antibody; ARF BP1 antibody; ARF-binding protein 1 antibody; ARF-BP1 antibody; ARFBP1 antibody; BJ-HCC-24 tumor antigen antibody; E3 ubiquitin protein ligase HUWE1 antibody; E3 ubiquitin-protein ligase HUWE1 antibody; HECT antibody; HECT domain protein LASU1 antibody; HECT UBA and WWE domain containing protein 1 antibody; HectH9 antibody; Homologous to E6AP carboxyl terminus homologous protein 9 antibody; Huwe1 antibody; HUWE1_HUMAN antibody; Ib772 antibody; Large structure of UREB1 antibody; LASU1 antibody; MCL 1 ubiquitin ligase E3 antibody; MCL-1 ubiquitin ligase E3 antibody; Mule antibody; UBA and WWE domain-containing protein 1 antibody; Upstream regulatory element-binding protein 1 antibody; URE-B1 antibody; URE-binding protein 1 antibody; UREB1 antibody;
Cat. No.: HY-13551C
CAS No.: 80277-14-1
Synonyms: m-AMSA isethionate; Acridinyl anisidide isethionate
Target:
Topoisomerase DNA/RNA Synthesis DNA Alkylator/Crosslinker ERK Akt GSK-3 Bcl-2 Family Caspase Apoptosis Potassium Channel
Research Areas:
Amsacrine isethionate (m-AMSA isethionate) is a Topoisomerase II inhibitor. Amsacrine isethionate intercalates into DNA. Amsacrine isethionate induces Ca 2+-mediated inactivation of ERK, and also downregulates AKT, promoting MCL1 downregulation mediated by GSK3β via reducing the phosphorylation level of GSK3β. Amsacrine isethionate induces Apoptosis by activating Caspase-9 and Caspase-3. Amsacrine isethionate blocks HERG potassium channels in the open/inactivated state. Amsacrine isethionate induces chromosomal aberrations and sister chromatid exchanges, and inhibits the synthesis of RNA and DNA. Amsacrine isethionate exhibits anti-leukemic activity. Amsacrine isethionate causes cardiac repolarization disorders, QT interval prolongation, ventricular arrhythmias, and increases the risk of sudden cardiac death. Amsacrine isethionate can be used in research related to acute myeloid leukemia, lymphoma and progressive malignancies [1] .
Cat. No.: HY-13551D
CAS No.: 80277-11-8
Synonyms: m-AMSA lactate; Acridinyl anisidide lactate
Target:
Topoisomerase DNA/RNA Synthesis DNA Alkylator/Crosslinker ERK Akt GSK-3 Bcl-2 Family Caspase Apoptosis Potassium Channel
Research Areas:
Amsacrine lactate (m-AMSA lactate) is a Topoisomerase II inhibitor. Amsacrine lactate intercalates into DNA. Amsacrine lactate induces Ca 2+-mediated inactivation of ERK, and also downregulates AKT, promoting MCL1 downregulation mediated by GSK3β via reducing the phosphorylation level of GSK3β. Amsacrine lactate induces Apoptosis by activating Caspase-9 and Caspase-3. Amsacrine lactate blocks HERG potassium channels in the open/inactivated state. Amsacrine lactate induces chromosomal aberrations and sister chromatid exchanges, and inhibits the synthesis of RNA and DNA. Amsacrine lactate exhibits anti-leukemic activity. Amsacrine lactate causes cardiac repolarization disorders, QT interval prolongation, ventricular arrhythmias, and increases the risk of sudden cardiac death. Amsacrine lactate can be used in research related to acute myeloid leukemia, lymphoma and progressive malignancies [1] .
Cat. No.: HY-148381
CAS No.: 2378056-80-3
Target:
Research Areas:
A947 is a VHL-based SMARCA2 PROTAC degrader with a DC50 of 39 pM and a Kd of 93 nM for human SMARCA2. A947 recruits SMARCA2 to the VHL E3 ubiquitin ligase for ubiquitination modification, mediates its degradation via the proteasome, and exerts selective degradation effects on SMARCA4 and PBRM1. A947 induces G1 cell cycle arrest, inhibits transcription, and exerts growth inhibitory effects in SMARCA4 G12C-mutant cancer cells. A947 acts synergistically with MCL1 inhibitors to induce apoptosis in SMARCA4 G12C-mutant cancer cells. A947 can be used in studies related to SMARCA4 G12C-mutant non-small cell lung cancer and non-small cell lung cancer [1] .
Cat. No.: HY-101778R
CAS No.: 315698-17-0
Synonyms: EU-5346 (Standard)
Target:
Research Areas:
ML311 (Standard) (EU-5346 (Standard)) is the analytical standard of ML311 (HY-101778). This product is intended for research and analytical applications. ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction.
Cat. No.: HY-N3913
CAS No.: 911004-72-3
Target:
Cat. No.: HY-N17676
CAS No.: 72424-02-3
Target:
Cat. No.: HY-139453A
CAS No.: 2412580-47-1
Target:
Research Areas:
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .
Cat. No.: HY-P991899
Synonyms: LCB73 Antibody
Target:
Research Areas:
Cat. No.: HY-187555
Research Areas:
MAPK-IN-9 is a ERK MAPK-MCL-1 inhibitor. MAPK-IN-9 activates caspase-7 and caspase-3, and cleaves poly (ADP-ribose) polymerase (PARP) to induce apoptosis. MAPK-IN-9 inhibits the clonogenic capacity of non-small cell lung cancer cells. MAPK-IN-9 can be used in research related to non-small cell lung cancer [1].
Cat. No.: HY-P991225
Target:
Research Areas:
Cat. No.: HY-182671
CAS No.: 2409965-28-0
SRX3305 is an BTK/PI3K/BRD4 inhibitor with IC50s of 6.5 nM, 15 nM, and 4 nM toward BTK, PI3Kɑ and PI3Kδ, respectively. SRX3305 attenuates chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) cell proliferation and promotes apoptosis in a dose-dependent fashion. SRX3305 yields potent anti-tumor effects but spares healthy bystander cells. SRX3305 inhibits the activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals. SRX3305 blocks CLL cell migration toward CXCL-12 and CXCL-13. SRX3305 maintains its anti-tumor effects in Ibrutinib (HY-10997)-resistant CLL cells. SRX3305 can be used for research in CLL, diffuse large B-cell lymphoma (DLBCL) and MCL .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
